Research programme: proteasome inhibitors - Telik
Latest Information Update: 11 Oct 2010
At a glance
- Originator Telik
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Mar 2008 Preclinical trials in Cancer in USA (PO)